In an era of enhanced integration of anti-HER2 treatments and while more young patients with early breast cancer are subjected to this class of therapeutic agents in addition to chemotherapy, it is mandatory to evaluate to effect of combined treatment on fertility for optimal patient counseling with regard to reproductive perspectives and treatment options. The gene discussed is ERBB2; the disease is breast carcinoma.